Publications by authors named "V Villemagne"
Background: The relationship between subtle cognitive decline and Alzheimer's disease (AD) pathology as measured by biomarkers in settings outside of specialty memory clinics is not well characterized.
Objective: To investigate how subtle longitudinal cognitive decline relates to neuroimaging biomarkers in individuals drawn from a population-based study in an economically depressed, small-town area in southwestern Pennsylvania, USA.
Methods: A subset of participants without dementia (N = 115, age 76.
The presence of multiple pathologies is the largest predictor of dementia. A major gap in the field is the in vivo detection of mixed pathologies and their antecedents. The Alzheimer's Disease Research Centers (ADRCs) are uniquely positioned to address this gap.
View Article and Find Full Text PDFArticle Synopsis
- Plasma phospho-tau 217 (pTau217) assays, when performed on the common Lumipulse-G® platform, can effectively identify Alzheimer's disease (AD) by analyzing β-amyloid (Aβ) status and tau staging in patients.
- In a study with 388 participants, pTau217 showed strong correlations with PET imaging results, achieving high accuracy rates in distinguishing between Aβ-negative and Aβ-positive individuals, as well as different stages of tau pathology.
- The findings suggest that the plasma pTau217 assay is a reliable tool for predicting who might benefit from anti-β-amyloid treatments, emphasizing its potential for broader clinical use in AD diagnostics.
Background: Blood-based biomarkers are gaining grounds for the detection of Alzheimer's disease (AD) and related disorders (ADRDs). However, two key obstacles remain: the lack of methods for multi-analyte assessments and the need for biomarkers for related pathophysiological processes like neuroinflammation, vascular, and synaptic dysfunction. A novel proteomic method for pre-selected analytes, based on proximity extension technology, was recently introduced.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the genetic factors contributing to Alzheimer's disease by analyzing tau deposition through a genome-wide association study involving 3,046 participants.
- It identifies the CYP1B1-RMDN2 locus as significantly linked to tau levels, with the variant rs2113389 explaining 4.3% of tau variation, while also correlating with cognitive decline.
- Findings suggest a connection between CYP1B1 expression and tau deposition, offering potential new avenues for Alzheimer's treatment and understanding its genetic basis.